Nucleoside Analogue-Based Supramolecular Nanodrugs Driven by Molecular Recognition for Synergistic Cancer Therapy-Reference-Cited by-同舟云学术

Nucleoside Analogue-Based Supramolecular Nanodrugs Driven by Molecular Recognition for Synergistic Cancer Therapy

Published:2018-06-25 Issue:28 Volume:140 Page:8797-8806
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Wang Dali¹,Yu Chunyang¹^ORCID,Xu Li¹,Shi Leilei¹,Tong Gangsheng¹,Wu Jieli¹,Liu Hong²^ORCID,Yan Deyue¹,Zhu Xinyuan¹^ORCID

Affiliation:

1. School of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People’s Republic of China

2. Institute of Theoretical Chemistry, State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun 130021, People’s Republic of China

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Colloid and Surface Chemistry,Biochemistry,General Chemistry,Catalysis

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.8b04556

Reference56 articles.

1. Principles of nanoparticle design for overcoming biological barriers to drug delivery

2. Nanomaterials for Drug Delivery